Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Met-Rx, AST To Place Warnings On "Andro" Products Under FTC Settlement

This article was originally published in The Tan Sheet

Executive Summary

Sports supplement marketers Met-Rx USA and AST Sports Science agree in individual settlements with the Federal Trade Commission to place warnings on their androstenedione ("andro") supplements as well as an additional warning on andro supplements also containing ephedra.
Advertisement

Related Content

Prop 65 Andro Settlements Include “Corrective Advertising” Provision
Prop 65 Andro Settlements Include “Corrective Advertising” Provision
Prop 65 Andro Settlements Include “Corrective Advertising” Provision
FDA/DEA Ban Of Andro Sought By Blue Cross & Blue Shield Foundation
Dietary Supplement Content Analyses On FTC Agenda For 2000
McGwire gives up andro
Andro Does Not Boost Muscle Mass Or Serum Testosterone Levels - Study
Androstenedione Nominated For NTP Toxicology Testing
Ephedra-containing dietary supplement across-the-board label warning suggested by FDA.
Ephedra-containing dietary supplement across-the-board label warning suggested by FDA.

Topics

Advertisement
UsernamePublicRestriction

Register

PS090588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel